Antibacterial activity of apramycin at acidic pH warrants wide therapeutic window in the treatment of complicated urinary tract infections and acute pyelonephritis

BACKGROUND: The clinical-stage drug candidate EBL-1003 (apramycin) represents a distinct new subclass of aminoglycoside antibiotics for the treatment of drug-resistant infections. It has demonstrated best-in-class coverage of resistant isolates, and preclinical efficacy in lung infection models. How...

Descripción completa

Detalles Bibliográficos
Autores principales: Becker, Katja, Cao, Sha, Nilsson, Anna, Erlandsson, Maria, Hotop, Sven-Kevin, Kuka, Janis, Hansen, Jon, Haldimann, Klara, Grinberga, Solveiga, Berruga-Fernández, Talia, Huseby, Douglas L., Shariatgorji, Reza, Lindmark, Evelina, Platzack, Björn, Böttger, Erik C., Crich, David, Friberg, Lena E., Vingsbo Lundberg, Carina, Hughes, Diarmaid, Brönstrup, Mark, Andrén, Per E., Liepinsh, Edgars, Hobbie, Sven N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577399/
https://www.ncbi.nlm.nih.gov/pubmed/34740109
http://dx.doi.org/10.1016/j.ebiom.2021.103652

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577399/
https://www.ncbi.nlm.nih.gov/pubmed/34740109
http://dx.doi.org/10.1016/j.ebiom.2021.103652

Ejemplares similares